NF North Central Educational Blog

In this NFNC Blog, we share stories regarding the latest research and breakthrough, information on events as well as stories from individuals and families impacted by NF.

If you would like to submit an article or story to be considered for our blog, please reach out to us.

Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1

Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas Selumetinib Is a MEK 1/2 Inhibitor Being Co-Developed by AstraZeneca and Merck KENILWORTH, N.J.–(BUSINESS WIRE)– AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted…